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ABSTRACT 
“A Study of Gastrointestinal Pathophysiology” 
Emily A. Minor 
 Though the duodenum is the primary site of iron absorption, the colon also 
contains iron transporters and participates in iron absorption. The purpose of this study 
was to characterize colonic iron absorption in control patients and those with ulcerative 
colitis (UC), a disease that frequently results in iron deficiency. Using RT-qPCR and 
western blot analysis, we found that colonic expression of the apical iron importer, 
divalent metal transporter 1 (DMT1), is equal to duodenal expression. However, colonic 
expression of ferroportin 1 (FPN1), an iron exporter, is only about one-quarter that of the 
duodenum. Patients with active ulcerative colitis were found to have increased DMT1 
(2x) and FPN1 (5X) in the colon. Immunostaining demonstrated that the transporters 
were localized to membrane (DMT1-apical, FPN1-basolateral) and 59Fe uptake studies 
revealed that the transporters contributed to increased colonic iron uptake in UC tissue, 
which may help alleviate the iron deficiency that is a frequent complication of UC.  
 Once we identified the colon as an ideal site to target for iron absorption in 
ulcerative colitis, we next wanted to determine whether it is safe to prescribe oral iron 
supplementation to patients with UC. Using an animal model of colitis, we found that 
oral iron supplementation led to increased disease activity. However, we cannot make 
any definitive conclusions without conducing a human clinical trial. If we find that 
colonic iron absorption is not a suitable treatment in UC then we can pursue it for other 
causes of iron deficiency, such as Celiac disease or gastric bypass. 
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Iron Homeostasis 
 
Iron is an essential nutrient that is required for many important physiological 
processes including redox reactions of the electron transport chain, oxygen transport, and 
DNA synthesis (1,2). Whole body and cellular iron concentration are tightly regulated 
because iron imbalance in either direction is detrimental to normal functioning (3). Iron 
overload results in the formation of damaging free radicals, while too little iron can lead 
to iron deficiency with subsequent anemia (4,5). The body lacks a coordinated excretory 
mechanism for iron, so homeostasis is therefore maintained at the level of absorption, 
which varies based on iron type (6,7).  
 Dietary iron exists in two forms: inorganic non-heme iron (~90%) and organic 
heme iron (~10%) (8). Heme iron comes from hemoglobin and myoglobin animal food 
sources (9). It represents only a small fraction of the total iron in ones diet, but it is more 
readily absorbed than non-heme iron and therefore makes up about 40% of the total iron 
absorbed (10). The majority of iron absorption occurs in the duodenum, the first part of 
the small intestine (11). Absorption of heme iron is not entirely understood, but there are 
two prevailing hypotheses: 1) receptor mediated endocytosis or 2) heme carrier protein 1 
(HCP1)-mediated transport across the apical membrane followed by liberation of iron via 
heme oxygenase 1 (HO-1) (12,13).  
Non-heme iron absorption has been much more extensively studied and is the 
focus of my research. Inorganic non-heme iron is found in both animal and plant sources 
where it predominantly exists in the ferric (Fe3+) form. Ferric iron is reduced to ferrous 
(Fe2+) iron by duodenal cytochrome b (Dcytb) and then transported across the apical 
membrane via divalent metal transporter 1 (DMT1) (14,15). DMT1 is a proton-coupled 
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transporter consisting of 12 transmembrane domains (16). There are four mRNA 
transcript variants: differing 5’ promoters that transcribe either DMT1 1A or 1B and 
alternate splicing of the 3’ UTR, leading to transcripts with or without the iron response 
element (IRE), (+IRE or –IRE) (17). Once inside the cell, iron can either be stored as 
ferritin or transported across the basolateral membrane by ferroportin 1 (FPN1), the only 
known iron exporter (16). See Figure 1 for a depiction of non-heme iron absorption. 
The daily iron absorption requirement is approximately one to two milligrams, 
which compensates for the iron lost due to sloughing of skin/mucosa and menstruation 
(18). Iron homeostasis is very tightly regulated, so the daily loss is quite small compared 
to the three to four grams of iron contained within the body, mostly present in circulating 
erythrocytes (hemoglobin), muscle myoglobin, and liver hepatocytes (19). The 
recommended daily allowance (RDA) for iron is eight milligrams per day for men and 
postmenopausal women and 18 mg per day for premenopausal women (20). This 
accounts for the fact that only about 10-15% of the iron in ones diet is actually absorbed 
in the duodenum (21). 
The absorption of iron is one critical mediator of whole body iron homeostasis, 
however, it is not the only one. Hepcidin, a 25 amino acid liver-derived hormone, is also 
an important negative regulator of iron status that is released in times of iron loading and 
inflammation (22). High iron levels are sensed by hepatocytes, while inflammation-
induced hepcidin production is signaled via IL-6 (23). Hepcidin leads to the 
internalization and ubiquitin-mediated degradation of FPN1 and can also directly occlude 
the channel (24,25). Inadequate hepcidin fails to limit iron absorption, resulting in iron 
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overload, as seen in hereditary hemochromatosis, commonly called bronze diabetes (26). 
Symptoms include arthritis, liver disease, diabetes mellitus, and skin discoloration (27).  
 
Iron Deficiency Anemia 
On the other end of the spectrum is iron deficiency, the most common nutrient 
deficiency worldwide, affecting approximately two billion people (4). Iron deficiency is 
the number one cause of anemia, defined as a reduction in the amount of circulating red 
bloods cells (28). The main burden of the disease falls on developing countries due to the 
increased incidence of poverty, famine, and a cereal-based diet in those areas (29). 
Children are particularly susceptible because of the increased demand for iron during 
periods of growth (30).  
Iron deficiency anemia (IDA) in the adult population is largely due to insufficient 
intake, impaired absorption, or blood loss (31). It is classified as a hypochromic, 
microcytic anemia with insufficient iron available for hemoglobin (Hb) production 
resulting in pale RBCs with reduced mean corpuscular volume (MCV). Symptoms 
include fatigue, weakness, cold intolerance, and difficulty concentrating (32). IDA can 
greatly reduce quality of life, as evidenced by several well-validated instruments used to 
document patient outcomes showing reduced quality of life (QOL) in patients with 
anemia (33). The broad detrimental impact of iron deficiency anemia (IDA) can be 
attributed to the critical role of iron in many biological processes, as described above 
(1,34).  
Diagnosis of anemia is typically achieved via blood draw and laboratory analysis 
of various RBC parameters (35). IDA is defined as Hb < 13.0 g/dL in adult males and Hb 
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< 12.0 g/dL in non-pregnant females (36). The reduction in Hb is accompanied by low 
serum iron, hematocrit (Hct), MCV, and transferrin saturation with an increase in total 
iron-binding capacity (TIBC). These particular laboratory findings help distinguish iron 
deficiency as the cause of anemia.  
 
Inflammatory Bowel Disease 
 
 Inflammatory bowel disease (IBD) is an umbrella term that encompasses both 
Crohn’s disease and ulcerative colitis (UC), two chronic, relapsing inflammatory diseases 
of the intestines (37). The exact etiology is unknown, but IBD is thought to be an 
autoimmune condition that results from aberrant host-microbiome interactions in a 
genetically susceptible individual (38). IBD affects more than three million people in the 
United States (>1% of the population) (38). Direct and indirect healthcare costs are 
estimated to be between $14.6 and $31.6 billion annually, making it one of the top five 
most expensive gastrointestinal (GI) disorders (39,40).  
Though IBD has some unifying features, Crohn’s disease and UC are very much 
different diseases. Crohn’s can occur anywhere in the digestive tract and typically 
involves transmural inflammation that is discontinuous (41). UC, on the other hand, only 
involves the colon with mucosal inflammation beginning in the rectum and extending 
proximally in a continuous manner to involve a variable length of the large intestine (42). 
UC is equally common in both sexes, while Crohn’s affects more females than males 
(43). Symptoms of both include diarrhea, bloating, and abdominal pain. Patients with 
Crohn’s present with more diffuse pain indicating both small bowel and colonic disease, 
whereas UC patients often present with bloody, mucous-laden diarrhea and pain more 
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localized to the area of affected colon (44). Characteristics of UC and Crohn’s disease are 
summarized in Figure 2.  
My research focuses specifically on ulcerative colitis, which has a higher 
incidence than Crohn’s disease, but is not as well studied (45). Diagnosis of UC is 
achieved first by obtaining a relevant history focusing on stool frequency, consistency, 
blood, and mucous content. Colonoscopy with biopsy is performed for a definitive 
diagnosis (42). Treatment depends on the severity and localization of the disease. For 
mild disease, a topical 5-aminosalicylic acid (5-ASA) is preferred. More extensive 
disease warrants oral and local 5-ASA administration plus corticosteroids, and in severe 
cases, immunomodulators (such as 6-mercaptopurine, a purine analog that inhibits 
nucleotide synthesis) and/ or biologics (such as humira, a TNFα inhibitor) may be 
necessary (46).  
 In addition to the symptoms described above, UC is also associated with various 
other manifestations. Because it is an autoimmune condition, patients are at an increased 
risk of developing other autoimmune diseases (47). UC patients also have a higher risk of 
developing colorectal cancer (CRC): 2% risk at 10 years, 8% at 20 years, and 18% at 30 
years (48). Peripheral arthritis, oral apthous ulcers, erythema nodosum, uveitis, 
ankylosing spondylitis, and primary sclerosing cholangitis also occur. 
 
Iron Deficiency Anemia in Ulcerative Colitis  
 Iron deficiency anemia (IDA) is the most common extraintestinal manifestation of 
UC (49). Approximately 70% of patients newly diagnosed with UC will develop IDA in 
the first 10 years after diagnosis, largely due to blood loss in areas ulceration and 
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impaired absorption as a result of inflammation and faster intestinal transit time (50,51). 
Female sex and extent of disease activity are the biggest risk factors for development of 
anemia (52). IDA has a large detrimental impact on quality of life in UC patients, can 
lead to hospitalization and delayed discharge, and results in an overall increase in the 
healthcare burden (53).  
 Oral iron supplementation is the first line therapy for IDA (18). It is simple, 
cheap, and cost effective. Various formulations exist including ferrous fumarate and 
ferrous gluconate, however, ferrous sulfate is the best tolerated and most commonly used 
clinically (54). Whether or not symptoms are present, all patients with IDA and most with 
iron deficiency should be treated because there is a clear benefit to treating iron 
deficiency-associated fatigue without anemia (55,56). Therapeutic Guidelines 
recommend a dose of 325-650 mg daily of ferrous sulfate, which is equivalent to 105-210 
mg of elemental iron (57). A one gram per deciliter increase in hemoglobin after one 
month of treatment indicates an adequate response to treatment (58). However, therapy 
should be continued for three months after the anemia is corrected in order for iron stores 
to replenish (59).  
 The biggest issue with oral iron supplementation is its tolerability. Some studies 
have shown that oral iron increases gastrointestinal side effects such as bloating, 
constipation, flatulence, tarry stools, and abdominal pain (60). This can lead to poor 
compliance with medication and failure to resolve the iron deficiency. One group found 
that as many as 40% of patients did not use their medication regularly, largely due to 
gastrointestinal issues and weight gain (61). There is still a debate in the literature about 
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the prevalence of side effects following oral iron administration with some groups finding 
minimal associated symptoms and others observing a large negative effect (62).  
 In cases of severe iron deficiency or failed response to oral iron, intravenous (IV) 
iron supplementation is required. IV iron leads to faster and greater increases in 
hemoglobin levels, but has the potential for some serious adverse effects, including 
anaphylactic shock (63). Older formulations, especially iron dextran, had an unacceptably 
high rate of adverse events. However, some of the newer preparations with a 
carbohydrate shell have proven to be much safer because they bind elemental iron more 
tightly, allowing for slower release (64). Though IV iron supplementation was touted as 
the more efficacious treatment for IDA with a lower side effect profile, recent studies 
have begun to dispute this finding. One group found no difference in side effects or 
hemoglobin levels following oral iron administration compared to IV iron (65). Some say 
that there is no evidence IV iron raises hemoglobin at a faster pace, nor that oral iron 
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A simplified schematic of non-heme iron absorption in the duodenum. Dietary ferric iron 
(Fe3+) is converted to ferrous iron (Fe2+) by duodenal cytochrome b (Dcytb). Ferrous iron 
is then transported across the apical membrane via divalent metal transporter 1 (DMT1). 
Once inside the cell, iron can either be stored as ferritin or exported across the basolateral 
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Chron’s Disease Ulcerative colitis
- Anywhere in the digestive tract
- Transmural inflammation
- Skip lesions
- Crampy abdominal pain
- Colon only  
  
- Mucosal inflammation
- Continuous disease activity
- Bloody diarrhea
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Increased apical and basolateral iron transporter expression  
with enhanced iron uptake in ulcerative colitis human colon 
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Specific Aims	  
 
(1) Localize non-heme iron transporters divalent metal transporter 1 (DMT1) and 
ferroportin 1 (FPN1) throughout normal human colon compared to duodenum.  
 
(2) Determine whether expression of DMT1 and FPN1 is altered in the distal colonic 
epithelium of patients with active ulcerative colitis (UC) compared to controls and 
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Abstract 
Iron deficiency anemia is a common complication of ulcerative colitis (UC) that can 
profoundly impact quality of life. Most iron absorption occurs in the duodenum via 
divalent metal transporter 1 (DMT1)-mediated uptake and ferroportin 1 (FPN1)-mediated 
export across the apical and basolateral membranes, respectively. However, the colon 
also contains iron transporters and can participate in iron absorption. Studies have shown 
increased duodenal DMT1 and FPN1 in patients with UC, but there is conflicting 
evidence about whether expression is altered in UC colon. We hypothesize that 
expression of colonic DMT1 and FPN1 are also increased to compensate for iron 
deficiency. RT-qPCR and western blot analyses were performed on duodenal and 
segmental colonic (right, transverse, left colon, and rectum) biopsies obtained during 
colonoscopy. Colonic DMT1 mRNA and protein abundance were approximately equal to 
duodenal levels, while colonic FPN1 abundance was about one-quarter that of the 
duodenum. In patients with UC, DMT1 mRNA and protein abundance in the colon were 
increased by two-fold, while FPN1 was increased by five-fold. Immunohistochemical 
(IHC) and immunofluorescence (IF) studies showed increased membrane localization of 
DMT1 (apical) and FPN1 (basolateral) in UC tissue. Iron uptake was also increased in 
UC distal colon compared to control. We conclude that patients with active UC have 
increased expression of colonic iron transporters and increased iron absorption, which 
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New and Noteworthy 
 
Our study examines expression of non-heme iron transporters in control and ulcerative 
colitis (UC) human colon. Apical DMT1 and basolateral FPN1 are abundantly expressed 
in the colons of healthy individuals. Patients with ulcerative colitis have increased 
colonic DMT1 and FPN1 transporter abundance and iron uptake, which may help 
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Introduction 
 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that is 
characterized by mucosal inflammation of the colon (9, 32). Inflammation typically 
begins in the rectum and extends proximally in a continuous manner to involve a variable 
length of the large intestine (8). Symptoms include diarrhea, hematochezia, abdominal 
pain, tenesmus, and bloating (16, 47). While gastrointestinal symptoms are the hallmark 
of the disease, other complications can arise, such as primary sclerosing cholangitis, 
colorectal cancer, various autoimmune conditions, and anemia (17, 19). 
Anemia in patients with UC is of particular importance because of its high 
incidence and impact on quality of life (2, 3, 36). As many as 70% of patients newly 
diagnosed with UC will develop anemia, defined as a reduction in the amount of 
circulating red bloods cells, over the first 10 years (22, 40). Symptoms include weakness, 
fatigue, dizziness, malaise, and difficulty concentrating (4, 43). Iron deficiency is by far 
the most common cause of anemia in UC patients, largely due to blood loss in areas of 
ulceration and malabsorption (7, 39). The broad detrimental impact of iron deficiency 
anemia (IDA) can be attributed to the critical role of iron in many biological processes, 
such as redox reactions of the electron transport chain, DNA synthesis, and oxygen 
transport (28).  
Iron handling is unique in that the body lacks a coordinated excretory mechanism 
(1). Homeostasis is therefore maintained at the level of absorption, the majority of which 
occurs in the duodenum (42, 48). Dietary iron comes in two forms, inorganic non-heme 
iron (90%) and organic heme iron (10%), which each have different absorption 
mechanisms (33). Inorganic iron, which exists in the ferric (Fe3+) form, is first reduced to 
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ferrous (Fe2+) iron by duodenal cytochrome b (Dcytb) and then transported across the 
apical membrane via divalent metal transporter 1 (DMT1) (10, 18). Once inside the cell, 
iron is either stored as ferritin or exported across the basolateral membrane via 
ferroportin 1 (FPN1) (51).  
The duodenum is the primary site of absorption, but the colon also contains iron 
transporters and can participate in iron absorption (5, 6, 35, 45). In fact, a recent study 
showed that DMT1 abundance in the colon was approximately equal to that in the 
duodenum, suggesting that the colon plays a more significant role in iron absorption than 
previously thought (52). It is known that duodenal DMT1 and FPN1 are increased in 
patients with UC, but there is conflicting evidence concerning the expression of these 
transporters in the colon. The purpose of this study was to investigate the expression and 
function of iron transporters in colonic tissue from UC patients and non-IBD controls. 
We hypothesize that colonic DMT1 and FPN1 abundance and iron absorption are 
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Materials and Methods 
Subject Recruitment 
All experiments were approved by the Institutional Review Board at West Virginia 
University (WVU). Written informed consent was obtained. Adults 18 years and older 
who were previously scheduled for colonoscopy with biopsy and/or endoscopy with 
biopsy at WVU’s Ruby Memorial Hospital were recruited into the study. Patients were 
enrolled during pre-op for their procedure with no preference given to a specific sex, age, 
or ethnicity. Participants were told the purpose of the study as well as the risks, benefits, 
and potential complications. Researchers had access to patient files including labs, 
medications, and diagnoses. Labs relevant to anemia status, hemoglobin (Hb) and 
hematocrit (Hct), were pulled from patient charts as close to the time of the procedure as 
possible. We also noted relevant medications including 5-aminosalicylic acids (5-ASA), 
immunomodulators, corticosteroids, and biologic agents. Patients on different medication 
regimens were used for each set of experiments in order to minimize the confounding 
effect of various treatments.  
Human Tissue Collection 
Duodenal and colonic biopsies were taken by a board-certified gastroenterologist using 
an Olympus colonoscope (Olympus Corporation of the Americas, Center Valley, PA) and 
jumbo biopsy forceps. Separate biopsies were taken for diagnostic purposes and for use 
in this study. For protein and transcript analysis, segmental biopsies were taken from the 
right, transverse, left colon, and rectum. Tissue for 59Fe experiments was taken from the 
distal colon due to the propensity for UC to affect the latter segments of the colon. 
Following collection, the biopsies were placed in cold saline solution on ice and 
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immediately transported to the lab. Colonoscopic images were also captured during the 
procedure. 
Histology  
Biopsies taken for diagnostic purposes were sent to the Pathology Department at West 
Virginia University (WVU) for analysis. Hematoxylin and eosin (H&E) staining was 
performed according to standard protocol in order to assess disease activity. Segmental 
biopsies allowed disease status assessment throughout the large intestine. Control patients 
had normal tissue histology and no history of IBD. UC patients were previously 
diagnosed with UC and had active disease activity on biopsy, as determined by a board-
certified pathologist.  
RNA Isolation and RT-qPCR Analysis 
RNA was extracted from duodenal and colonic tissue immediately after collection using 
an RNEasy kit per manufacturer’s instructions (Qiagen, Valencia, CA). Concentrated 
RNA was quantified using a Nanodrop 1000 (Thermo, Waltham, MA) and then stored at 
-80°C until further use. Quantitative reverse transcription polymerase chain reaction (RT-
qPCR) analysis was performed using a one-step kit (New England Biolabs, Ipswich, 
MA). The protocol consisted of 10 minutes reverse transcription of RNA (50 ng/well) 
followed by quantitative PCR using a dsDNA-binding dye. DMT1, FPN1, and 
phosphoglycerate kinase (PGK; a housekeeping gene) gene specific custom forward and 
reverse primers (400 nM primers/well) were designed using the NCBI Primer-BLAST 
application (Table 1). The ΔΔCt method was used to determine fold change of transcripts 
in reference to PGK. PGK threshold cycles for each gene were subtracted from the 
threshold cycles of the transcripts of interest to determine the ΔCt value. The average ΔCt 
	   29 
from the control samples was then subtracted from the ΔCt value of UC samples to obtain 
a ΔΔCt value. Fold changes for the transcripts of interest were calculated as 2-ΔΔCt.  
Protein Isolation and Western Blot Analysis 
Biopsy specimens were placed in 150 µL of radioimmunoprecipitation assay (RIPA) 
buffer containing full protease inhibitor cocktail (cOmplete, Mini, Sigma-Aldrich, St. 
Louis, MO). The tissue was homogenized using a glass homogenizer, briefly sonicated, 
and then centrifuged at 12,500 RPM for 15 minutes. Protein was stored at -80°C until 
further use. On the day of immunoblotting, protein concentration was determined using 
the Pierce BCA protein quantification kit (Thermo, Waltham, MA). Samples were diluted 
to 1 µg/µl with deionized water and 4x Laemmli buffer (Bio-Rad, Hercules, CA) and then 
heated to 60°C for 10 minutes. Bolt 4-12% Bis-Tris Plus Gels (Thermo, Waltham, MA) 
were loaded with 20 µg/well of protein, run at 135 V, and then transferred to a 
nitrocellulose membrane for one hour at 30 V. Nitrocellulose membranes were blocked in 
3% BSA for one hour at room temperature followed by incubation with primary antibody 
overnight at 4°C: FPN1 1:1,000 (Alomone Labs, Jerusalem, Israel), DMT1 1:4,000 
(Abcam, Cambridge, UK), β-actin 1:1,000 (Cell Signaling, Danvers, MA) (12, 27, 41, 
49). The next morning, the membranes were washed five times for five minutes in TBST 
and then placed in goat-anti rabbit horseradish peroxidase-conjugated secondary antibody 
(1:20,000) for two hours at room temperature. The membranes were washed again and 
imaged on a G:Box Chemi XX9 (Syngene, Cambridge, UK). Target proteins were 
quantified using ImageJ and normalized to β-actin using densitometric analysis of band 
intensity.  
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Immunostaining 
Immunohistochemical (IHC) staining was performed on control and UC distal colonic 
epithelium at the University of Cincinnati. Sectioned tissues were incubated in DMT1 
(1:50, Abcam- ab55735, Cambridge, UK) or FPN1 (1:200, Abcam- ab85370) primary 
antibody for one hour at 37°C. The tissues were then placed in goat anti-rabbit 
horseradish-peroxidase conjugated secondary antibody (1:1,000) for one hour at room 
temperature. A chromogenic substrate was used for visualization of slides and images 
were captured on an AxioImager at 40x magnification (Carl Zeiss, Germany).  
Immunofluorescence (IF) studies were performed on 15 µm sections of distal 
colonic tissue. Formalin fixed sections hydrated in PBS for 30 minutes were 
permeabilized with PBS containing 0.1% triton (PBST) for 15 minutes. Tissue sections 
were incubated with 5% goat serum to block nonspecific binding prior to incubation with 
DMT1 (Abcam, Cambridge, UK) or FPN1 (Alomone Labs, Jerusalem, Israel) primary 
antibodies (1:500) for 18 hours. Sections were washed with PBS (3x) then incubated in 
fluorescently labeled secondary antibody (DMT1: goat anti-mouse IgG Alexa Fluor 488, 
FPN1: goat anti-rabbit IgG Texas Red, 1:1,000, Thermo, Waltham, MA) for 2 hours at 
room temperature. The sections were washed again with PBS (3x) and images were 
captured using a confocal microscope (Zeiss 710, Oberkochen, Germany).  
Iron Uptake Studies 
Biopsies from the distal colonic epithelium of control subjects were weighed and 
incubated in DMEM at 37° C for 10 minutes. After this equilibration period, 59Fe  (NEN 
Radiochemicals PerkinElmer, Waltham, MA) was added to the media for 2, 5, 10, 30, or 
60 minutes. The tissue was washed 10x with PBS and whole tissue iron uptake was 
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measured using a Tri-Card 4810 TR liquid scintillation analyzer (PerkinElmer, Waltham, 
MA). Uptake was reported as counts per minute (CPM) per gram (g) of tissue. Analysis 
of 59Fe uptake in control tissues revealed linear uptake kinetics between 2 and 10 minutes 
with saturation of uptake occurring by approximately 30 minutes (Figure 8A). 59Fe 
uptake in control versus UC distal colonic epithelium was therefore evaluated at two and 
five minutes, as that corresponded to linear uptake.  
Statistics  
GraphPad Prism 6.0 (San Diego, CA) was used for statistical analyses. All results are 
expressed as means ± SE. Control and UC groups were compared using a Student’s t-test. 
For analyses involving more than two groups, a one-way ANOVA was performed. 
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Results 
Patient Demographics and Disease Status  
Colonic biopsies were taken from 26 control and 25 patients with UC. There was 
no significant difference in sex (male/female: control 12/14, UC 14/11) or age (control 
42.5 ± 3.7, UC 50.7 ± 3.5 years, p > 0.10) between the groups. Control colons exhibited 
normal gross morphological appearance on colonoscopy with pink mucosa, visible 
haustra, and no inflammation (Fig. 1, Top left panel). Histological evaluation revealed 
intact crypts with no evidence of pathology (Fig. 1, Bottom left panel). UC colons had 
macroscopically visible inflammation and ulceration (Fig 1; Top right panel) with 
destruction of crypt architecture and a large influx of inflammatory cells, including 
neutrophils and macrophages (Fig. 1, Bottom right panel).  
Patients with UC had lower levels of Hb (control 14.81 ± 0.35 vs. UC 13.50 ± 
0.36, p < 0.05) and Hct (control 43.39 ± 0.95 vs. UC 40.23 ± 0.97, p < 0.05) compared to 
controls. While most patients did not meet the criteria of anemia, there was a statistically 
significant reduction in Hb and Hct, suggesting iron deficiency with sub-clinical anemia.   
Localization of DMT1 Along Normal Human Colon Compared to Duodenum 
Animal studies have shown decreasing abundance of DMT1 and FPN1 from 
duodenum down the gastrointestinal tract to the colon (20). However, characterization of 
these transporters has not yet been described in humans. We focused our studies first on 
the apical iron importer, DMT1. Using the duodenum as a frame of reference, we 
evaluated the relative abundance of DMT1 in each distinct region of control colon (i.e. 
right colon, transverse colon, left colon, rectum). RT-qPCR analysis revealed that DMT1 
specific mRNA abundance in the colon was approximately equal to that in duodenum, 
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and that DMT1 transcript abundance was relatively uniform throughout the length of the 
colon (Fig. 2A: duodenum 1.06 ± 0.15, right colon 1.32 ± 0.30, transverse colon 0.80 ± 
0.16, left colon 1.16 ± 0.25, rectum 1.03 ± 0.19, n = 6, p > 0.50 for all multiple 
comparisons). Similarly, DMT1 protein abundance in the colon was also found to be 
approximately equal to that in the duodenum and was relatively uniform throughout 
colonic segments (Fig. 2, B and C: duodenum 1.00 ± 0.36, right colon 0.75 ± 0.10, 
transverse colon 1.05 ± 0.17, left colon 0.84 ± 0.17, rectum 0.89 ± 0.18; n = 5, p > 0.90 
for all multiple comparisons).  
DMT1 Expression in UC Compared to Control Distal Colon 
 Once we confirmed the presence and established the localization of DMT1 in 
healthy human colons, we next sought to determine whether expression is altered in 
ulcerative colitis. All experiments were conducted in the distal colon, as this region is 
predominately affected in UC (24). Patients with UC had a two-fold increase in DMT1 
mRNA abundance compared to controls (Fig. 3A: control 1.00 ± 0.05 vs. UC 2.22 ± 0.60, 
n = 7 for control, n = 5 for UC, p < 0.05).  DMT1 protein abundance was also doubled in 
UC tissue (Fig. 3, B and C: control 1.02 ± 0.23 vs. UC 1.95 ± 0.33, n = 5, p < 0.05).  
We performed immunohistochemistry (IHC) in order to determine whether the 
increased transporters were localized to the plasma membrane. DMT1 was diffusely 
located throughout the membrane in control distal colonocytes and was increased, largely 
on the apical membrane, in patients with active ulcerative colitis (Fig. 4, A and B). In 
order to identify the precise membrane specific localization, immunofluorescence (IF) 
studies were performed. As shown in Fig. 4C, DMT1 was primarily located on the apical 
and subapical membranes of surface and upper crypt cells in control colon. In UC colon, 
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DMT1 expression was increased on the apical membrane of both surface and crypt cells 
(Fig. 4D).   
Localization of FPN1 Along Normal Human Colon Compared to Duodenum 
 After examining changes in the iron import protein, DMT1, we next characterized 
the only known iron exporter, ferroportin. RT-qPCR analysis showed that FPN1 specific 
mRNA abundance was uniform throughout the length of the colon, although transcript 
abundance was about one-quarter that of the duodenum (Fig. 5A: duodenum 1.09 ± 0.18, 
right colon 0.34 ± 0.11, transverse colon 0.30 ± 0.10, left colon 0.32 ± 0.11, rectum 0.40 
± 0.15, n = 6, p < 0.01 for multiple comparisons vs. duodenum, p > 0.98 for multiple 
comparisons within the colon). Western blot analysis of FPN1 revealed equal protein 
expression throughout the length of the colon, and similar to RT-qPCR findings, colonic 
protein levels were approximately one-quarter that of the duodenum (Fig. 5, B and C: 
duodenum 1.00 ± 0.21, right colon 0.31 ± 0.05, transverse colon 0.30 ± 0.05, left colon 
0.25 ± 0.05, rectum 0.36 ± 0.10, p < 0.05 vs. duodenum, n = 5, p > 0.99 for all other 
multiple comparisons). 
FPN1 Expression in UC Compared to Control Distal Colon 
 Patients with UC had a five-fold increase in FPN1 mRNA abundance in distal 
colonic epithelium compared to controls (Fig. 6A: control 1.07 ± 0.14 vs. UC 5.32 ± 
0.82, n = 7 for control, n = 5 for UC, p < 0.05). FPN1 protein abundance in UC tissue 
was also approximately five times greater than control (Fig. 6, B and C: control 1.01 ± 
0.14 vs. UC 4.9 ± 0.87, n = 6, p < 0.05). IHC showed that FPN1 was minimally 
expressed in control colon and was increased on the basolateral membrane in UC (Fig. 7, 
A and B). IF revealed that in control tissue, FPN1 was present on surface cell 
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membranes, but similar to DMT1, was expressed to a lesser extent within the crypts (Fig 
7C). In UC, FPN1 expression was increased on the basolateral membrane of surface cells 
and in the crypts (Fig. 7D).  
59Fe in Control vs. UC Distal Colonic Epithelium  
Finally, we sought to determine whether the increased DMT1 and FPN1 
transporter abundance in UC tissue was correlated with increased iron uptake. In vitro 
59Fe uptake in control tissue was evaluated at 2, 5, 10, 30, and 60 minutes. Linear uptake 
occurred from 2 to 10 minutes and began to saturate by 30 minutes (Fig. 8A, n = 6 at 2 
and 5 minutes, n = 4 at 10 minutes, n = 3 at 30 and 60 minutes). 59Fe uptake into UC 
tissue was approximately double that of control at two and five minutes (Fig. 8B: control 
8,853 ± 1,547 vs. UC 19,051 ± 1,685 at 2 minutes; control 16,022 ± 1,431 vs. UC 30,819 
± 2,315 at 5 minutes, n = 6 for control, n = 7 for UC, p < 0.05).  
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Discussion 
Though the duodenum is the primary site for iron absorption, the colon is also 
equipped with the necessary iron transport machinery and is exposed to high levels of 
dietary iron (21, 30). Studies have shown the capacity for the human colon to participate 
in iron absorption and found that colonic DMT1 expression is approximately equal to that 
in the duodenum (52). However, a systematic analysis of the expression of these iron 
transporters through different segments of the colon (i.e. left colon, transverse colon, 
right colon, rectum) has not yet been reported in the literature.  
By obtaining biopsies from patients scheduled for endoscopy or colonoscopy with 
biopsy, we were able to determine colonic iron transporter abundance in comparison to 
duodenal levels in control (non-IBD) patients. In line with previous studies, we found 
that DMT1 mRNA and protein abundance in the colon were approximately equal to that 
in the duodenum and were relatively uniform throughout the length of the colon (Fig. 2). 
FPN1 expression was also uniform throughout the colon, but its abundance was only 
about one-quarter that of the duodenum (Fig. 5). The lower colonic expression of FPN1 
may explain why the rate of iron absorption in the colon is less than that of the 
duodenum.  Additionally, it suggests that FPN1-medaited export is likely the rate-
limiting step of colonic iron absorption.  
Once we characterized expression of DMT1 and FPN1 in control colons, we next 
wanted to examine the expression of these transporters in patients with active UC 
because iron deficiency is such a common complication of the disease. Iron transporters 
are increased in the duodenum of patients with IBD, so we expected increased DMT1 and 
FPN1 in the colon, as well (44). In support of our hypothesis, we found that DMT1 and 
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FPN1 mRNA and protein abundance were increased in the distal colons of patients with 
active ulcerative colitis (Fig. 3 and 6). DMT1 mRNA and protein levels were doubled, 
while FPN1 levels were five times greater in UC compared to control. The significant 
increase in FPN1 to approximately the same abundance as control duodenum suggests 
that patients with active UC may be able to up-regulate colonic iron absorption to near 
duodenal levels.  
One previous study evaluated the expression of iron transporters in IBD and 
found that DMT1 was decreased in the inflamed mucosa of active UC, in opposition to 
our findings (52). Investigators did not specify which part of the colon the biopsies came 
from nor whether changes were determined in the same segment of the colon for each 
group, which may explain the discrepancy. Further, changes in protein abundance were 
not evaluated. By contrast, our group examined both mRNA and protein abundance and 
only compared control and UC tissue taken from the distal colon in order to maintain 
consistency.  
After establishing that distal colonic DMT1 and FPN1 transporter abundance 
were increased in UC patient biopsies, we next sought to localize DMT1 and FPN1 
within the membrane. IHC staining showed increased apical DMT1 and basolateral FPN1 
in UC distal colon. IF was also carried out to allow for better localization of transporters. 
DMT1 and FPN1 were found on surface cells in control distal colon, but few transporters 
were located within the crypts. Patients with UC were confirmed to have increased apical 
DMT1 and basolateral FPN1 on surface cells and increased expression of transporters 
within the crypts (Figs. 4 and 7).  
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Localization of DMT1 and FPN1 to apical and basolateral membranes, 
respectively, in UC, lends credence to the possibility that these transporters can 
contribute to iron absorption. To demonstrate this functionality in vitro, we analyzed 59Fe 
uptake in control versus UC distal colonic epithelium. We first determined the time 
course for iron uptake in control tissue and then compared uptake in control and UC 
tissue at two and five minutes, as that corresponded to linear uptake. At both two and five 
minutes, 59Fe uptake in UC tissue was approximately double that of control, supporting 
the notion that the increased transporters in UC patients are functional and able to 
facilitate enhanced iron absorption (Fig. 8). 
The mechanism underlying increased colonic expression of iron transporters in 
UC is likely tied to whole body regulation of iron homeostasis via hepcidin, the main iron 
regulatory hormone that is produced in the liver in response to high iron levels and 
inflammation (14, 15, 23, 50). Hepcidin leads to the internalization and degradation of 
FPN1, thereby inhibiting iron absorption in the intestine and preventing the release of 
iron from hepatocytes and macrophages in times of iron overload (11, 37). Iron 
deficiency is also a key regulator of hepcidin production. When serum iron is low, 
soluble hemojuvelin binds to and inhibits the bone morphogenetic protein (BMP)/SMAD 
pathway of hepcidin synthesis (13). Additionally, impaired erythropoietic activity, as 
seen in anemia, down-regulates hepcidin mRNA abundance (25, 34).  
Although we did not measure hepcidin levels, we can infer that circulating 
hepcidin is reduced in the patients with ulcerative colitis. UC patients had lower levels of 
Hb and Hct compared to controls, indicating subclinical anemia, which would lessen 
hepcidin production via the pathways described above. In fact, hepcidin has been shown 
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to be reduced in patients with IBD, demonstrating that iron deficiency is the key regulator 
of hepcidin production regardless of inflammatory status (31). We therefore predict that 
the enhanced colonic iron absorption in patients with UC is the result of reduced hepcidin 
levels leading to increased expression of FPN1. FPN1-mediated export is likely the rate-
limiting step of colonic iron absorption, so maximizing FPN1 expression is the key to 
enhancing iron absorption in the colon.  
The functional significance of increased colonic iron absorption in patients with 
active UC is that the colon could help alleviate iron deficiency. Under normal 
physiological conditions, the colon may play only a small role in iron absorption, 
however, in the times of deficiency, colonic iron absorption may increase to near 
duodenal levels.   
The enhanced colonic absorptive capacity in patients with active UC suggests that 
they are prime candidates for oral iron supplementation. In general, some physicians have 
shied away from prescribing oral iron to patients with UC, as there is evidence to suggest 
that it may exacerbate disease activity (29, 46). However, recent findings reveal no 
difference in gastrointestinal symptoms following oral iron supplementation compared to 
intravenous (IV) administration in IBD patients (26, 38). Oral iron remains the preferred 
treatment for iron deficiency anemia because of its safety, efficacy, and convenience. 
Increased colonic iron absorption in UC, as the data from this study suggests, provides 
support for the use of oral iron supplementation as the first line treatment of iron 
deficiency anemia in patients with ulcerative colitis. 
In conclusion, non-heme iron transporters DMT1 and FPN1 are abundantly 
expressed in human colon and are increased in patients with active UC. These findings 
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suggest that the colon plays a more significant role in iron absorption than previously 
thought and that colonic iron absorption may become particularly important in times of 
deficiency. Perhaps the colon can even be targeted for iron absorption as a novel 
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Figure Captions 
Figure 1: Morphological and histological analyses of control and ulcerative colitis (UC) 
human colons. Images of control (top left panel) and UC (top right panel) colons were 
captured during colonscopy. Control colons exhibited pink mucosa with no signs of 
inflammation, while UC colons had visible inflammation and ulceration. Hematoxylin 
and eosin (H&E) staining of control (bottom left panel) and UC (bottom right panel) 
colonic biopsy specimens. Control colons contained highly organized crypts, while UC 
colons exhibited destruction of crypt architecture, crypt abscesses, and numerous 
inflammatory cells (neutrophils and macrophages). Typical images presented represent 
data acquired from 6 different control and UC patients.  
 
Figure 2: Divalent metal transporter 1 (DMT1) mRNA abundance and protein expression 
in control human colon segments with respect to duodenum. [A] RT-qPCR analysis 
revealed that DMT1 mRNA abundance throughout the colon was approximately equal to 
that in the duodenum (n = 6, p > 0.50 for all multiple comparisons). [B] Western blot 
analysis of FPN1 in epithelial cell homogenates from duodenum and colon. Western blots 
were quantified via densitometry and normalized to β-actin. [C] Quantitative analyses 
indicated that the relative protein abundance of DMT1 in colon segments was not 
significantly different from that in the duodenum (n = 5, p > 0.90 for all multiple 
comparisons). Duodenal DMT1 protein expression was quite variable between patients.  
 
Figure 3: Increased divalent metal transporter 1 (DMT1) mRNA abundance and protein 
expression in ulcerative colitis (UC) distal colon. [A]: RT-qPCR analysis revealed a two-
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fold increase in DMT1 mRNA abundance in UC tissue compared to control (control n = 
7, UC n = 5, p < 0.05). [B]: Representative images of western blots for DMT1 and β-actin 
in control and UC tissue. [C]: Quantitative analyses of DMT1, normalized to β-actin, 
showed that DMT1 protein abundance in UC patients was approximately double that of 
controls (n = 5, p < 0.05). * p < 0.05 compared to control.  
 
Figure 4: Cell and membrane specific localization of divalent metal transporter 1 (DMT1) 
in control and ulcerative colitis (UC) human distal colon. [A] Immunohistochemical 
(IHC) staining revealed that DMT1 was diffusely present on the apical membrane of 
control tissue (arrows). [B] DMT1 was increased, largely on the apical membrane, in UC 
colon (arrows). [C] Immunofluorescence (IF) studies demonstrated that in control colons, 
DMT1 (green) was present primarily on the surface cells and upper crypt cells (bracket). 
[D] In UC colon, DMT1 staining was increased on the apical membrane of surface cells 
(arrows) and within the crypts (asterisk). Cell nuclei were localized with blue staining 
Hoeschst33342. Similar images were obtained from three different control and UC colon 
specimens for each staining method. IHC images were captured at 40x magnification. 
Scale bars in IF images represent 50 µm.  
 
Figure 5: Ferroportin 1 (FPN1) mRNA abundance and protein expression in control 
human colon segments with respect to duodenum. [A] RT-qPCR analysis revealed that 
FPN1 mRNA abundance in the colon was reduced compared to the duodenum, but did 
not significantly differ throughout the length of the colon (n = 6, p < 0.01 for multiple 
comparisons vs. duodenum, p > 0.98 for multiple comparisons within the large intestine). 
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[B] Western blot analysis of FPN1 in epithelial cell homogenates from duodenum and 
colon. Western blots were quantified via densitometry and normalized to β-actin. [C] 
Quantitative analyses showed that FPN1 abundance in the colon was about one-quarter 
that of the duodenum, but its abundance did not significantly differ within the colon (n = 
5, p < 0.05 vs. duodenum, p > 0.99 for all other multiple comparisons). * p < 0.05 
compared to duodenum.  
 
Figure 6: Increased ferroportin 1 (FPN1) mRNA abundance and protein expression in 
ulcerative colitis (UC) distal colon. [A] RT-qPCR analysis revealed a 5-fold increase in 
FPN1 mRNA abundance in UC tissue compared to control (control n = 5, UC n = 7, p < 
0.05). [B] Western blot analysis of FPN1, normalized to β-actin, in control and UC distal 
colonic epithelium. [C] Quantitative analyses of western blots revealed that FPN1 protein 
abundance in UC tissue was five times greater than control (n = 6, p < 0.05). * p < 0.05 
compared to control.  
 
Figure 7: Cell and membrane specific localization of ferroportin 1 (FPN1) in control and 
ulcerative colitis (UC) distal colon. [A] Immunohistochemical (IHC) staining revealed 
that FPN1 was minimally present on the basolateral membrane of control colon (arrows). 
[B] FPN1 expression was increased, largely on the basolateral membrane, of UC colon 
(arrows). There were also more immune cells in the lamina propria (asterisk). [C] 
Immunofluorescence (IF) studies revealed that FPN1 (red) was present primarily on 
surface cells and upper crypt cells (bracket). [D] In UC, FPN1 was increased on both the 
basal (arrows) and lateral (arrow heads) membranes of surface cells. FPN1 staining was 
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also substantially increased on the basolateral membrane of crypt cells (asterisk). Cell 
nuclei were localized with blue staining Hoeschst33342. Similar images were obtained 
from three different control and UC colon specimens for each staining method. IHC 
images were captured at 40x magnification. Scale bars in IF images represent 50 µm.  
 
Figure 8: Increased 59Fe uptake in UC distal colonic epithelium. [A] Time course of 59Fe 
uptake in control tissue expressed as counts per minute (CPM) per gram (g) of tissue. 
Linear uptake occurred between 2 and 10 minutes and became saturated by 30 minutes (n 
= 3-6 for each time point). [B] 59Fe uptake in UC tissue was approximately double that of 
control at 2 and 5 minutes (n = 6-7, p < 0.005). * p < 0.05 compared to control.  
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Tables 
Table 1: Divalent metal transporter 1 (DMT1), ferroportin 1 (FPN1), and 
phosphoglycerate kinase 1 (PGK1) gene specific primers 
Gene Primers (Forward and Reverse)  Product length (bp) Melting Temp (°C) 
DMT1 
NM_001174125.1 
F: CTCCCGGAATATGGAGCCC 126 F: 59.32 
R: ATCTTCTGTTCAGGACCCAGC R: 59.72 
FPN1 
NM_014585.5 
F: TCTCTCTACTTGGGGAGATCGG 147 F: 60.16 
R: CAGTCACCGATGATGGCTCC R: 60.53 
PGK1 
NM_000291.4 
F: CTGTGTAGGCCCAGAAGTGG 137 F: 60.04 
R: GCTCGGCTTTAACCTTGTTCC R: 59.80  
 
Human DMT1, FPN1, and PGK1 gene specific forward (F) and reverse (R) primers were 
designed based on mRNA sequences obtained from the NCBI primer-blast application.  
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Oral iron supplementation exacerbates dextran sulfate sodium (DSS)-induced colitis 
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Background 
 
Animal Models of Colitis   
 There are a variety of inflammatory bowel disease (IBD) animals models: 
chemically induced colitis, cell transfer, and genetically engineered knockouts (16). 
Chemical induction is achieved by administering trinitrobenzene sulfonic acid (TNBS) 
rectally or dextran sulfate sodium (DSS) in the drinking water (24). TNBS activates 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and best 
recapitulates Crohn’s disease, while DSS better recapitulates ulcerative colitis (UC) (2, 
5). Cell transfer models involve the intraperitoneal injection of CD4+ T cells isolated via 
flow cytometry (16). Finally, genetically engineered models have been created by 
knocking out various IBD-associated genes including interleukin-10 (IL-10), signal 
transducer and activator of transcription 3 (STAT3), and human leukocyte antigen B27 
(HLA-B27), among others (17).  
 We chose to use DSS in our study because it is a inexpensive, quick, and effective 
method to reproducibly induce an ulcerative-like phenotype in mice (5). Another benefit 
of DSS is that you can easily control the extent of colitis based on the concentration and 
duration of exposure. The molecular weight of DSS is an important factor in colitis 
induction, with the most severe colitis resulting from 40 kDa DSS. We therefore used the 
36-50 kDa formulation of DSS for this study, which was administered in the drinking 
water for six days, followed by one day of recovery.  
Mouse strain also has an impact on DSS colitis induction. BALB/c mice were 
selected because they mount a predominantly T helper cell 2 (Th2)-type immune 
response, which is most similar to human ulcerative colitis (26).  
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Oral Iron Supplementation in Ulcerative Colitis 
 As detailed previously, iron deficiency anemia (IDA) is a frequent complication 
of ulcerative colitis. Up to 70% of UC patients develop anemia within the first 10 years 
after diagnosis (12). Oral iron supplementation is the first line treatment for IDA, but this 
can be problematic because oral iron is associated with gastrointestinal side effects and 
may exacerbate disease activity in UC (7). Other groups, however, have found no 
association between oral iron and increased disease activity (1, 8).  Additional research is 
needed to determine the safety of prescribing oral iron supplementation to patients with 
ulcerative colitis, as well as potential causal mechanisms between iron and disease 
exacerbation.  
 
Microbiome in Healthy Adults 
 The microbiome is composed of 1014 resident microorganisms (bacteria, fungi, 
viruses, and protozoa) (23). Bacteria found in healthy adults come from four main phyla: 
Firmicutes, Bacteriodetes, Proteobacteria, and Actinobacteria (6). The Firmicutes are 
gram-positive and made up of two main classes: bacillales and clostridia (95%) (22). 
Bacteriodetes are gram-negative and comprise the majority of the bacteria in the gut of 
most individuals (25). Actinobacteria are gram-positive and include Streptomyces, 
actinomyces, proprionobacteria, corynebacteria, among others (3). Finally, Proteobacteria 
are divided into alpha, beta, gamma, delta, and epsilon groups and include a lot of 
pathogenic bacteria, such as E. coli, pseudomonas, and Neisseria (21).  
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Microbiome in Ulcerative Colitis 
Profound differences in microbial composition and diversity have been found in 
patients with ulcerative colitis compared to their healthy counterparts, but there is much 
debate about whether microbial dysbiosis is a primary causal instigator of intestinal 
inflammation or whether inflammation is the driving force that causes shifts in the 
microbiome (9, 15). Recent evidence suggests that both likely occur with the microbiome 
of UC patients characterized by increased pathogenic bacteria and decreased species 
richness (14). Specifically, a reduction in Firmicutes and increase in Bacteriodetes and 
facultative anaerobes is known to occur (10).  
The reduction in Firmicutes bacteria is particularly detrimental because this 
phylum contains an extremely important group of microbes known as butyrate-producing 
bacteria (BPB). Butyrate is the primary energy source for colonocytes, suppresses 
inflammation, and increases mucin production, so adequate production is necessary (4). 
Patients with UC experience a reduction in butyrate producers leading to decreased 
butyrate levels, uptake, and oxidation (19). Most BPB are members of clostridial cluster 
IV or XIVa (20).  
 
Effect of Iron Supplementation on the Microbiome  
 Ulcerative colitis has a negative impact on microbiome composition, as does oral 
iron supplementation. Several studies in African school children have shown that iron 
fortification decreases the abundance of beneficial commensal bacteria, such as 
Bifidobacteria and Lactobacilli, and increases the abundance of Enterobacteria, including 
E. coli (11, 18). High iron has also been associated with decreased butyrate-producing 
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bacteria (13). Iron supplementation to patients with ulcerative colitis may therefore be 
particularly dangerous, as those patients already have a pathogenic microbial profile that 
could be further negatively altered.   
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Specific Aims 
 
(1) Determine if oral iron supplementation exacerbates dextran sulfate sodium (DSS)-
induced colitis. Balb/c mice with and without DSS colitis will be given standard chow or 
a diet supplemented with ferrous sulfate for one week. We will examine changes in 
disease activity by monitoring body weight, colon length, fecal consistency and blood 
content, histology, and cytokine production.  
 
(2) Examine changes in microbiome composition following oral iron supplementation in 
animals with DSS-induced colitis. Terminal restriction fragment length polymorphism 
(TRFLP) will be utilized to determine changes in the microbiome, particularly butyrate-
producing bacteria (BPB).  
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Abstract	  
	  
 Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that is 
characterized by diarrhea, abdominal pain, and bloody, mucous-laden stools. Blood loss 
is severe enough to cause iron deficiency anemia (IDA) in one third of patients, making it 
the most common extra-intestinal manifestation of UC. Oral iron supplementation is the 
first line treatment for IDA, but there is a debate about whether oral iron is safe to give 
patients with UC. Some studies have found that oral iron exacerbates disease activity, 
while others say it is well tolerated and efficacious. The purpose of this study was to 
determine whether oral iron exacerbates dextran sulfate sodium (DSS)-induced colitis in 
mice, a model that effectively recapitulates ulcerative colitis. We hypothesize that iron 
supplemented chow will increase disease activity and lead to pathogenic changes in the 
microbiome in mice with DSS colitis. Iron supplementation resulted in a higher disease 
activity index (DAI), lower percent dry weight of feces, and increased inflammatory 
cytokines compared to DSS alone. However, there was no difference in colonic lengths 
or histological scores between the DSS and DSS + iron groups. We conclude that iron 
supplementation does increase colitis severity, though further experiments are needed to 
determine the extent of disease exacerbation and whether the same effect occurs in 
humans. Ongoing experiments will also determine whether iron alters microbiome 
composition, which could partially explain changes in disease activity.  
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Introduction 
	  
 Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that is 
characterized by bloody, mucous-laden stools (18, 19). Symptoms include diarrhea, 
abdominal pain, bloating, and tenesmus (34). The exact etiology of UC is unknown, but it 
is thought to result from a complex interplay between the environment, genetic 
susceptibility, and microbial dysbiosis, all of which contribute to a chronic inflammatory 
state in the colon (3). Approximately one million people in the United States have been 
diagnosed with ulcerative colitis, a number that has been rising over the past several 
decades (13, 31). The disease affects less than one percent of the population, but it 
imposes a tremendous economic burden, estimated to be between $8.1 and $14.9 billion 
annually in the US alone, largely due to frequent physician visits and hospitalizations, 
complications necessitating surgery, and expensive therapeutics (12, 36).  
 Though disease activity is limited to the colonic mucosa, the amount of 
inflammation and blood loss is severe enough to cause iron deficiency in 60-80% of 
patients (21). One third of people go on to develop anemia, making iron deficiency 
anemia (IDA) the most common extraintestinal manifestation of UC (52). Iron is an 
essential nutrient, so deficiency leads to a myriad of negative outcomes (7). Symptoms of 
IDA include weakness, fatigue, difficulty regulating body temperature, and impaired 
cognitive performance (5). The widespread detrimental impact of iron deficiency can be 
attributed to the fact that iron is involved in many important physiological processes 
including redox reactions of the electron transport chain, oxygen transport, and DNA 
synthesis (1, 17). 
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 Oral iron supplementation is the first line treatment for IDA, but its use is 
controversial (42). In non-IBD patients, oral iron administration is associated with 
gastrointestinal side effects such as nausea, flatulence, diarrhea, and constipation (52). In 
patients with ulcerative colitis, oral iron has been shown to exacerbate disease activity, 
leading to poor medication compliance and relapse of anemia (33, 50). Increased disease 
activity following oral iron administration in animal models of colitis has also been 
observed (9, 10). However, other studies have found no such association between oral 
iron and increased disease activity in patients with UC (30, 49). 
We sought to determine whether oral iron supplementation increases disease 
activity in an animal model of colitis. Dextran sulfate sodium (DSS) was used to induce 
colitis in BALB/c mice over a one-week timeframe. The exact mechanism by which DSS 
induces colitis is not known, but it produces symptoms and histological changes 
consistent with ulcerative colitis and is favored because of its simplicity, rapidity, and 
reproducibility (11, 14, 16). BALB/c mice were selected because they have a 
predominantly T helper cell 2 (Th2)-type immune response when exposed to DSS, which 
most accurately reflects ulcerative colitis in humans (59). We assessed changes in disease 
activity using multiple parameters and also investigated whether iron alters microbial 
composition, which might help explain the changes in disease activity.  
We hypothesize that oral iron supplementation will increase disease activity and 
lead to pathogenic changes in the microbiome. Specifically, we expect to see a reduction 
in butyrate-producing bacteria (BPB), a heterogeneous group of microbes that generate 
butyrate, a short chain fatty acid (SCFA) that promotes colonic health (8, 58). BPB 
largely belong to Clostridium cluster IV and XIVa in the phylum Firmicutes, and include 
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microbes such as Faecalibacterium prausnitzii and Roseburia spp (25, 32). Adequate 
butyrate production is important because butyrate is the main energy source for 
colonocytes, induces mucin production, and has various anti-inflammatory effects (15, 
23, 60). Patients with UC are known to have decreased butyrate, so we expect the mice 
with DSS colitis to have fewer BPB than controls (29, 35, 44). Iron is also known to 
reduce the amount of BPB, so we hypothesize that the mice with DSS-induced colitis fed 
an iron supplemented diet will have an even further reduction in butyrate producers (28).   
Changes in microbial composition will be assessed via terminal restriction 
fragment length polymorphism (TRFLP). This technique enables identification and 
quantitative analysis of microbes based on their terminal restriction fragment size (53, 
55). Polymerase chain reaction (PCR) is conducted using fluorescently labeled primers 
that amplify the16S ribosomal ribonucleic acid (rRNA) gene and then the product is 
restriction digested and run on a sequencer (46). Microbial Community Analysis (MiCA), 
an online database that performs virtual PCRs and restriction digestions, was utilized for 




	   	  
	   76 
Materials and Methods 
	  
Animals 
All experiments were approved by the Institutional Animal Care and Use Committee at 
West Virginia University. Male BALBc/AnNCrl mice (7 weeks old, Charles River, NY) 
were selected because they mount a predominantly T helper 2 (Th2)-type immune 
response when exposed to DSS, which best replicates human ulcerative colitis (59). The 
mice were given two weeks to acclimate to the animal facility prior to use in experiments 
and then randomly divided into four groups:  
Control groups: 
(1) Control (Con) animals received standard chow and standard drinking water. 
(2) Iron (Fe) only animals received iron supplemented chow and standard 
drinking water. 
DSS groups: 
 (3) DSS only (DSS) animals received standard chow and drinking water with 5% 
DSS. 
(4) DSS plus iron (DSS+Fe) animals received iron supplemented chow and 
drinking water with 5% DSS. 
There were six animals per group, housed three to a cage on a 12 hour light-dark cycle.  
Induction of Colitis and Iron Supplemented Diet  
The mice were concurrently given the iron-supplemented diet for seven days and DSS 
(molecular weight 36-50 kDa, MP Biomedicals, Solon, OH) for six days followed by one 
day of standard drinking water. Standard chow (2018 Teklad Global 18% Protein Rodent 
Diet, Huntingdon, UK) contained 200 parts per million (ppm) ferrous sulfate, while the 
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iron supplemented diet (2018 Teklad Global 18% Protein Rodent Custom Diet, 
Huntingdon, UK) contained 600 ppm ferrous sulfate. Food and water were available ad 
libitum and consumption was tracked daily for each cage. On the eighth day, animals 
were anesthetized with 5% isoflurane prior to euthanasia via cervical dislocation.  
Disease Activity Index 
 
Disease activity index (DAI) was calculated daily for each animal as the average of three 
parameters: weight loss, stool consistency, and fecal blood content, as adapted from other 
groups (26, 57). Scores were defined as follows: 
• Weight loss: 0 (no loss), 1 (1-5% loss), 2 (5-10% loss), 3 (10-15% loss), 4 (>15% 
loss) 
• Stool consistency: 0 (normal, firm pellet), 2 (loose, sticky, very soft pellet), 4 
(diarrhea and/or mucous) 
• Fecal blood content: 0 (none), 1 (hemoccult positive), 2 (flecks of blood), 3 (gross 
blood), 4 (gross blood + blood on anus) 
Hemoccult blood was evaluated from two fecal pellets per animal per day (Hemoccult 
SENSA, Beckman Coulter, Brea, CA).  
Colon Lengths 
On the day of animal sacrifice, colons were removed via careful dissection and length 
was determined from cecum to anus, as described elsewhere (61). Colonic shortening was 
used a maker of increased inflammation and also occurs in ulcerative colitis patients (20, 
22, 43).   
Percent Fecal Dry Weight  
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Fecal pellets were collected daily from each animal for determination of percent fecal dry 
weight and for use in TRFLP experiments. Following collection, feces were immediately 
placed on ice and transported to the lab. Fecal pellets were frozen in liquid nitrogen and 
then placed at -80°C for a minimum of 24 hours. Pellets were weighed (wet weight), 
lyophilized for 24 hours, and then a dry weight was determined. Percent fecal dry weight 
was calculated as [(dry weight/wet weight) x 100]. A lower percent fecal dry weight 
indicates a looser stool and increased disease activity.  
Isolation of Colonic Epithelial Cells 
Colons were removed and rinsed with cold PBS. The distal colon was separated and 
opened along the mesenteric border, cut into small segments (~2 mm), and then rinsed 
with cold PBS five times. Tissue segments were placed in PBS with 5 mM 
ethylenediaminetetraacetic acid (EDTA) and gently rocked at 37°C for 30 minutes. 
Following this incubation period, the tissue was washed in cold PBS fives times and then 
vigorously shaken in 5 mL of PBS. The disrupted colonic crypts and epithelial cells were 
pelleted by spinning down the supernatant at 1,000 g for fives minutes.  
RT-qPCR Analysis of Colitis-Associated Cytokines 
An RNEasy kit (Qiagen, Valencia, CA) was used to extract RNA from isolated colonic 
epithelial cells immediately after collection. RNA was quantified with a Nanodrop 1000 
(Thermo Fisher Scientific, Waltham, MA) and then stored at -80°C. Quantitative reverse 
transcription polymerase chain reaction (RT-qPCR) analysis was carried out using a one-
step kit (New England Biolabs, Ipswich, MA) consisting of 10 minutes reverse 
transcription of RNA (50 ng/well) followed by quantitative PCR using a dsDNA-binding 
dye. Gene specific custom forward and reverse primers (400 nM primers/well) for 
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various ulcerative colitis-associated cytokines were created using the NCBI Primer-
BLAST application (Table 1). Fold changes of transcripts were calculated using the ΔΔCt 
method in reference to the housekeeping gene beta-actin (β-actin). ΔCt was calculated by 
subtracting β-actin threshold cycles from the threshold cycles of the transcripts of 
interest. The average ΔCt from the control samples was then subtracted from the ΔCt 
value of the group of interest to obtain a ΔΔCt value. Finally, fold changes were 
calculated as 2-ΔΔCt.  
Histology 
 
A small piece of intact distal colon was fixed in 10% neutral-buffered formalin for 24 
hours and then sent to the Translational Pathology Department at West Virginia 
University for histological analysis. The tissue was paraffin embedded, mounted on glass 
slides (5 µM thick sections), and hematoxylin and eosin (H&E) stained according to 
standard protocol. A board-certified pathologist who was blinded to treatment condition 
scored the slides based on a scoring system modified from a pervious study (51). An 
average score was calculated for each group based on extent of inflammatory cell 
infiltrate and tissue damage:  
• Cell infiltration (0- occasional inflammatory cells in the lamina propria, 2-confluence 
of inflammatory cells extending into the mucosa, 3- transmural extension of 
inflammatory cells) 
• Tissue damage (0- no damage, 1- partial loss of crypts in large areas, 2- partial to total 
loss of crypts with epithelium intact, 3- total loss of crypts with epithelium lost).  
DNA Extraction and Polymerase Chain Reaction (PCR) 
Microbial DNA was extracted from ~50 mg of lyophilized feces using a commercially 
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available bead beader kit (Quick-DNA Fecal/Soil Microbe Kit, Zymo Research, Irvine, 
CA) and quantified using a Nanodrop 1000 (Thermo Fisher Scientific, Waltham, MA). A 
50 µL PCR reaction was prepared with 1X Taq Master Mix (Apex 2X Taq Master Mix, 
Clear, Genesee Scientific, San Diego, CA), 150 ng of DNA, forward 5’ FAM-labeled 
degenerate primer: AGMGTTYGATYMTGGCTCAG (Y= C or T, M= A or C) and 
reverse 5’ NED-labeled primer: ATTACCGCGGCTGCTGG. The primers were adapted 
from Walker et al (56). PCR conditions were as follows: 95°C for 5 minutes, 10 cycles of 
95°C for 30 seconds, 57°C for 30 seconds, and 72°C for 90 seconds, 10 cycles of 95°C 
for 30 seconds, 51°C for 30 seconds, and 72°C for 90 seconds, 25 cycles of 95°C for 30 
seconds, 49°C for 30 seconds, and 72°C for 90 seconds followed by 72°C for 10 minutes. 
Products were expected between 173 and 530 base pairs.  
Terminal Restriction Fragment Length Polymorphism (TRFLP) 
A DNA clean and concentrator kit was used to remove primer-dimers and all products 
less than 50 base pairs (Zymo Research, Irvine, CA). PCR products were then digested in 
a 50 uL reaction using 0.5 uL of HpyCH4V or 1 uL of Hpy188I CutSmart enzymes, 1X 
CutSmart Buffer, (New England Biolabs, Ipswich, MA) and 6 uL of product. Restriction 
digestion was carried out at 37°C for one hour followed by 20 minutes at 65°C for 
enzyme inactivation. Restriction fragments were visualized using a 2% agarose gel. 
TRFLP was carried out on an ABI Prism 310 Genetic Analyzer (Thermo Fisher 
Scientific, Waltham, MA) with POP-4 polymer and a 37 cm short read capillary. 
Products (2 uL) were co-loaded with 12 uL formamide (Thermo Fisher Scientific, 
Waltham, MA) and 0.5 uL ROX-500 size standard (Red DNA Size Standard, Molecular 
Cloning Laboratories, San Francisco, CA) per reaction. Samples were run at 60°C for 35 
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minutes. GeneScan analysis software was used for fragment analysis to determine peak 
height and area. TRFLP Analysis Expedited (Trex) was used to align peaks and cleanse 
the data, Microbial Community Analysis III (MiCA III) to identify species, and 
APLAUS+ to determine relative abundance and community structure.  
Statistics 
Statistical analyses were performed using Graph Pad Prism 6.0 (San Diego, CA). When 
comparing more than two groups, a one-way ANOVA was used with n = 6 for each 
group. Results are expressed as means ± SE with significance set at p < 0.05.  
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Results 
 
Daily Food and Water Consumption 
 Food and water consumption was tracked daily for each group. Day 1 corresponds 
to the food and water consumption from 0-24 hours, Day 2 for 24-48 hours, and so on. 
Food consumption was approximately 15 grams of chow per group per day, which 
equates to about 2.5 grams of chow per animal (Fig. 1A). All groups ate approximately 
the same amount, indicating that differential food consumption could not explain 
differences in weight gain. Additionally, we can conclude that the groups receiving the 
iron-supplemented chow consumed the same total amount of iron.  
Water consumption was more variable, ranging from 20 to 30 milliliters of water 
per day per group, or roughly three to five milliliters per animal each day (Fig. 1B). 
Importantly, the DSS groups (DSS and DSS+Fe) drank approximately the same volume 
throughout the duration of the study. DSS was provided in the drinking water, so we can 
conclude that the groups receiving DSS received the same total amount of DSS.  
Oral Iron Supplementation Exacerbates DSS colitis  
 Changes in disease activity were monitored using multiple assays. Disease 
Activity Index (DAI) was determined daily for each animal, which is calculated as the 
average of three parameters: weight loss, stool consistency, and fecal blood content. The 
mice received a score from zero to four for each parameter, as detailed in the figure (Fig. 
2A). The average daily score for the control groups (control and iron only) remained 
approximately zero for the duration of the study (Fig. 2B). The DAI for the DSS groups 
(DSS only and DSS+Fe) steadily increased throughout the study. On Day 7, the DSS 
groups had a DAI of approximately 2.2, which was significantly higher than the control 
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groups (p < 0.05). The DSS+Fe group had a DAI of 3.1, which was higher than all other 
groups (p < 0.05). In order to determine which parameters contributed most to changes in 
disease activity, the total DAI was broken down into each separate parameter on Day 7 
(Fig. 2C). DSS groups had a significantly higher score on all parameters compared to 
control groups (p < 0.05). Weight loss contributed the least to total DAI, and there was no 
significant difference between the DSS groups, while stool consistency and fecal blood 
content contributed much more to DAI and the DSS+Fe group had a significantly higher 
score than DSS only (p < 0.05).  
 Colon lengths were determined on the day of animal sacrifice as a marker for 
inflammation, where colonic shortening correlates with increased inflammation and 
disease activity. Representative images of colons from each group demonstrated that the 
colons from the DSS groups (DSS only and DSS+Fe) were significantly shorter than the 
colons from the control groups (control and iron only) (Fig. 3A). Quantification of colon 
lengths revealed that control colons were approximately 12.62 ± 0.22 centimeters long, 
iron only colons were 12.38 ± 0.57, DSS only colons were 8.37 ± 0.09, and DSS+Fe 
colons were 7.38 ± 0.21 centimeters (Fig. 3B). Colons from the DSS groups were 
significantly shorter than the control groups, but there was no difference in colonic length 
between DSS only and DSS+Fe (p < 0.05).  
 We also determined the percent dry weight of feces on Day 1 and Day 7. A lower 
percent fecal dry weight indicates a looser stool and higher disease activity. On Day 1, all 
groups had a percent fecal dry weight of approximately 45%, and there was no significant 
difference between the groups (Fig. 4A, p > 0.05). On Day 7, the percent dry weight of 
the control groups remained 45%, while the fecal dry weight of the DSS only group was 
	   84 
reduced to 38% (p < 0.05 compared to control groups) and the DSS+Fe group to 31% 
(Fig. 4B, p < 0.05 compared to all other groups).  
 Cytokines that are involved in the development of colitis were also evaluated via 
RT-qPCR analysis. TNFα is the hallmark of DSS colitis, while IL-6 and IL-17 are 
associated with disease onset and progression (11). Relative mRNA abundance of all 
cytokines was increased in the DSS groups compared to the control groups (Fig 5, A-C, p 
< 0.05). TNFα and IL-6 were increased to a greater extent in the DSS+Fe group 
compared to DSS only (p < 0.05).  
 Histological changes were determined via H&E staining. The control groups 
contained highly organized test tube-shaped crypts (Fig. 6, A and B). DSS groups 
exhibited loss of crypt architecture and an influx of inflammatory cells (Fig. 6, C and D). 
The calculated histology score for the DSS groups was higher than for the control groups, 
but there was no significant difference between DSS only and DSS+Fe (Fig. 6E, p < 
0.05). 
Oral Iron Supplementation Alters Microbiome Composition 
 Experiments to determine changes in the microbiome are ongoing. Primers and 
restriction enzymes have been selected and verified, but we are still optimizing PCR 
conditions.   
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Discussion 
 Iron deficiency anemia (IDA) is a frequent complication of ulcerative colitis (UC) 
that results from a combination of fecal blood loss and impaired iron absorption (2, 37). 
Oral iron supplementation is the first line treatment for IDA, but its use is not without 
controversy (40). In otherwise healthy individuals, oral iron is associated with 
gastrointestinal side effects that sometimes compromise treatment compliance and 
efficacy (4, 38, 54). In patients with UC, oral iron has been shown to exacerbate disease 
activity. Other groups, however, have found no such association between oral iron and 
increased disease activity, and have, therefore, deemed oral iron to be well tolerated and 
efficacious in treating UC-related anemia (30, 39).   
The purpose of this study was to determine whether oral iron supplementation 
exacerbates disease activity in an animal model of colitis. We hypothesized that oral iron 
would exacerbate DSS-induced colitis and lead to pathogenic changes in the microbiome. 
BALB/c mice with and without DSS colitis were provided standard chow or chow 
supplemented with ferrous sulfate for one week as part of an acute experimental study. 
Fecal pellets were collected and disease activity was monitored daily for each animal.  
 DSS groups (DSS only and DSS+Fe) had increased disease activity on all 
parameters compared to control groups (control and iron only), as evidenced by increased 
disease activity indices (DAI), shorter colons, lower percent fecal dry weight, increased 
inflammatory cytokines, and higher histology scores (Figs. 2-6). The DSS animals 
developed symptoms and histological changes consistent with UC, confirming the 
validity of the experimental model. Specifically, the DSS animals experienced weight 
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loss, bloody, mucous-laden diarrhea, and destruction of colonic crypts with a large influx 
of inflammatory cells.  
 Compared to DSS alone, the DSS+Fe group developed even more significant 
disease activity on multiple parameters, including a higher DAI, lower percent fecal dry 
weight, and increased inflammatory cytokines. However, there was no difference in 
colonic lengths or histology scores between the DSS groups. We conclude that iron 
supplementation does exacerbate DSS colitis, but we cannot determine whether the 
observed changes would occur in humans, nor whether symptoms would be noticeably 
worsened in patients with UC. 
 The mechanism by which iron exacerbates colitis is likely tied to its generation of 
reactive oxygen species (ROS) via the Fenton and Haber-Weiss reactions (6). ROS can 
directly damage lipids, proteins, and deoxyribonucleic acid (DNA), and can also recruit 
inflammatory cells via the up-regulation of adhesion molecules and generation of 
chemotactic factors (24, 27). We also hypothesized that iron would lead to pathogenic 
changes in the microbiome, which may partially explain the increased disease activity in 
the DSS+Fe group. TRFLP experiments are ongoing to determine whether that is the 
case.  
 DSS-induced colitis is a great way to study ulcerative colitis in vitro, however, it 
is just a model and, therefore, cannot fully capture the intricacies of the disease in 
humans. One major concern is that the mechanism by which DSS induces colitis may 
magnify the negative effects of iron supplementation. DSS is a colitogen that is directly 
toxic to colonocytes, so DSS colitis may be more amenable to iron-induced damage than 
	   87 
is the case in humans with UC (41, 45). The only way to definitely determine whether 
oral exacerbates UC is to conduct a human clinical trial (see future directions).   
The significance of this study is that clinicians perhaps need to reconsider using 
oral iron supplementation as the first line treatment for IDA in patients with ulcerative 
colitis. Increased disease activity and pathogenic changes in the microbiome may be 
major contraindications to the use of oral iron in UC patients. Gastrointestinal side effects 
are reversible upon discontinuation of the oral iron, but disruption in microbial 
composition can leave a lasting negative impact. Pathogenic changes in the microbiome 
can cause an inflammatory response that leads to relapse of colitis or failure to respond to 
therapy (47). Physicians could avoid this myriad of negative outcomes by simply using 
intravenous (IV) iron supplementation as the first line treatment for IDA. Guidelines for 
clinician prescribing and insurance coverage of IV iron would need to be addressed in 
order to encourage the use of IV iron supplementation to treat UC-related anemia. 
 Iron deficiency anemia is a common complication of ulcerative colitis that is most 
commonly treated with oral iron supplementation. We found that iron supplemented 
chow increases disease activity in mice with DSS colitis, and, therefore, conclude that 
oral iron supplementation also likely exacerbates ulcerative colitis.  
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Figure Captions 
Figure 1: Total daily food and water consumption per group of animals per day. [A] 
Each group of animals (n = 6 per group) consumed approximately 15 grams of chow each 
day, which equates to roughly 2.5 grams eaten per mouse per day. Food consumption 
remained consistent between groups throughout the duration of the study. We can 
therefore conclude that the two groups receiving the iron-supplemented diet received 
approximately the same total amount of iron. [B] Total daily water consumption was 
slightly more variable throughout the duration of the study (between 20 and 30 milliliters 
per group per day). Importantly, the animals receiving dextran sulfate sodium (DSS)-
supplemented drinking water consumed roughly the same amount of fluids, and thus, 
received the same amount of DSS.  
 
Figure 2: Disease activity index (DAI). [A] The table depicts the scoring system used to 
determine DAI, calculated as the average of weight loss, stool consistency, and fecal 
blood content. Each animal was scored daily on each parameter. [B] The control groups 
(con and Fe) had a DAI of approximately zero throughout the duration of the study. The 
DAI of the DSS groups (DSS only and DSS+Fe) steadily increased throughout the 
duration of the study, reaching a maximum score on Day 7 of 2.2 and 3.1, respectively. 
The DAI for DSS only animals on day 7 was higher than both control groups, while the 
DSS+Fe group was significantly higher than all other groups. [C] DAI score on Day 7 for 
each parameter. The DSS groups had higher scores on all three parameters compared to 
the control groups. Weight loss contributed a small amount to total DAI and there was no 
significant difference between the DSS groups, while stool consistency and fecal blood 
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content contributed more to DAI and were higher for the DSS+Fe group compared to 
DSS alone. n = 6 for all groups,* p < 0.05 compared to control groups (con and Fe), $ p < 
0.05 compared to DSS only. 
 
Figure 3: Colon lengths measured from cecum to anus on the day of animal sacrifice. [A] 
Representative images of excised colons from each group. [B] Group data of colon 
lengths. The average length of a control (con) colon was 12.62 ± 0.22 centimeters, an 
iron (Fe) only colon 12.38 ± 0.57, a DSS only colon 8.37 ± 0.09, and a DSS+Fe colon 
7.38 ± 0.21. DSS only and DSS+Fe colons were significantly shorter than control colons 
(con and Fe groups). n = 6 for all groups, * p < 0.05 compared to control groups (con and 
Fe).  
 
Figure 4: Percent dry weight of feces on Day 1 and Day 7. [A] On Day 1, the average 
percent fecal dry weight was the same for all groups (~45%). [B] On Day 7, the percent 
fecal dry weight for the control groups (con and Fe) remained approximately 45%. The 
DSS only group had a lower percent fecal dry weight than the control groups (38%), and 
the DSS+Fe group was lower than all other groups (31%). n = 6 for all groups, * p < 0.05 
compared to control groups (con and Fe), $ p < 0.05 compared to DSS only. 
 
Figure 5: RT-qPCR analysis of cytokines involved in the development of colitis. [A] 
Relative mRNA abundance of TNFα was increased in the DSS groups (DSS only and 
DSS+Fe) compared to control groups (con and Fe), and was significantly higher in the 
DSS+Fe group compared to DSS alone. [B] IL-6 mRNA abundance was also increased in 
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the DSS groups compared to control groups, and was highest in the DSS+Fe group. [C] 
IL-17 mRNA abundance was higher in the DSS+Fe group compared to the control 
groups. n = 6 for all groups,* p < 0.05 compared to control groups (con and Fe), $ p < 
0.05 compared to DSS only. 
 
Figure 6: Hemotoxylin and eosin (H&E) staining of mouse distal colonic epithelium. [A] 
Control (con) colons exhibited highly organized test tube-shaped crypts. [B] The iron 
(Fe) only group also exhibited highly organized crypts with no visible inflammation. [C] 
DSS only colons depicted loss of crypt architecture with an influx of inflammatory cells. 
[D] DSS+Fe colons also experienced crypt destruction and inflammatory cell infiltrate. 
[E] Histology scoring was completed by a board-certified pathologist as the average of 
two parameters: inflammatory cell infiltrate and tissue damage. Control groups (con and 
Fe) had an average score of 0.17 ± 0.17, DSS only 2.00 ± 0.0, and DSS+Fe 2.33 ± 0.33. 
The histology score for the DSS groups (DSS and DSS+Fe) was higher than the control 
groups, but was not significantly different between the DSS groups. n = 3 for all groups, 
* p <0.05 compared to control groups (con and Fe). 
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Tables  
Table 1: Tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), interleukin 17 
(IL-17), and beta-actin (β-actin) gene specific primers 
	  
Gene Primers (Forward and Reverse)  Product length (bp) Melting Temp (°C) 
TNFα 
NM_013693.3 
F: GTAGCCCACGTCGTAGCAAA 137 F: 60.39 
R: ACAAGGTACAACCCATCGGC R: 60.32 
IL-6 
NM_031168 
F: TGAGAAAAGAGTTGTGCAATGG 168 F: 57.43 
R: GGTACTCCAGAAGACCAGAGG R: 58.90 
IL-17 
NM_010552.3 
F: CATGACTACACCCACCTCCC 185 F: 59.46 
R: CCTGTCATTTTGTCCAATTCATCG R: 59.90 
β-actin 
NM_007393.5 
F: AGATCAAGATCATTGCTCCTCC 165 F: 57.65 
R: AGTAACAGTCCGCCTAGAAGC R: 59.52  
	  
Mouse TNFα, IL-6, IL-17, and β-actin gene specific forward (F) and reverse (R) primers 
were designed using mRNA sequences obtained from the NCBI primer-blast application. 



































Food consumption Water consumption
	   101 
Figure 2 
 


























































Con Fe DSS DSS+Fe
Con Fe DSS DSS+Fe
*A B
*

































Con Fe DSS+FeDSS Con Fe DSS+FeDSS









































Con Fe DSS DSS+Fe Con Fe DSS DSS+Fe
IL-17 *
A B C








































Conclusions and Future Directions  
	   107 
Conclusions 
 In Chapter II, we made significant headway in understanding colonic iron 
absorption in healthy individuals and those with ulcerative colitis (UC). The colon has 
been shown to contribute to iron absorption in experiments dating as far back as the 
1960s (13). However, very little research had been done since then to understand the role 
of the colon in iron absorption and whole body iron homeostasis. We are the first group 
to show that DMT1 and FPN1 are expressed in equal abundance throughout the length of 
the colon. While colonic DMT1 mRNA and protein are equal to duodenal levels, FPN1 
abundance is only about one-quarter that of the duodenum. We therefore conclude that 
FPN1-mediated transport of iron across the basolateral is the rate-limiting step of colonic 
iron absorption and that the key to maximizing colonic iron absorption is to increase 
expression of FPN1.  
 Our group also studied expression of these transporters in patients with UC 
because iron deficiency anemia (IDA) is a common complication of the disease and can 
be challenging to treat. We found that DMT1 and FPN1 mRNA and protein abundance 
are increased in the distal colons of patients with active ulcerative colitis. DMT1 
expression is doubled, while FPN1 expression is approximately five times greater than 
control. The significant increase in FPN1 is especially important because FPN1 is the 
rate-limiting step of colonic iron absorption. Colonic FPN1 abundance is increased to 
approximately duodenal levels in patients with UC, suggesting that the colon can increase 
its absorptive capacity to match that of the duodenum.  
 The mechanism underlying the increased expression of iron transporters in UC 
patients is likely tied to whole body regulation of iron homeostasis via hepcidin, a liver-
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derived hormone released in times of iron overload and inflammation (15). Hepcidin 
leads to the internalization and degradation of FPN1, thereby limiting iron absorption in 
the intestines and release of iron from hepatocytes and macrophages (6). On the flip side, 
in times of iron deficiency, hepcidin levels are decreased to maximize the amount of 
FPN1.  
Hepcidin was previously thought to be increased in UC because it is a chronic 
inflammatory condition (14). However, recent advances have shown that iron deficiency 
is the key regulator of hepcidin production regardless of inflammatory status and that 
hepcidin is actually decreased in patients with ulcerative colitis (2, 3, 12). Decreased 
hepcidin in UC would allow increased FPN1 expression and increased iron absorption, as 
observed in this study.  
 The functional significance of increased expression of colonic iron transporters in 
UC is that the colon could help alleviate iron deficiency. In healthy individuals, the colon 
may play only a small role in iron absorption, but in times of deficiency its absorptive 
capacity can increase to meet demand. It may also mean that the colon can be targeted for 
iron absorption in other diseases that are frequently associated with IDA, such as celiac 
disease.  
 Once we found that there are increased iron transporters in the colons of patients 
with active ulcerative colitis, we next wanted to determine the safety of prescribing oral 
iron supplementation to UC patients. There is a debate in the literature about whether oral 
iron produces gastrointestinal side effects and worsens ulcerative colitis (10, 11). Recent 
studies have found that oral iron does not increase disease activity and is equally as 
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efficacious as intravenous (IV) iron (7, 9). In order to study this for ourselves, we carried 
out an animal study, as detailed in Chapter III. 
 Animals with and without DSS-induced colitis were provided either standard 
chow (200 ppm ferrous sulfate) or an iron-supplemented diet (600 ppm ferrous sulfate). 
We tracked changes in disease activity using several well-established parameters 
including disease activity index (DAI), colon length, percent dry weight of feces, 
cytokine profiling, and hematoxylin and eosin (H&E) staining. Animals with DSS-
induced colitis given an iron-supplemented diet had increased DAI and inflammatory 
cytokines and decreased percent dry weight of feces compared to DSS alone. However, 
there was no change in colon length or H&E staining.  
We conclude that oral iron exacerbates DSS colitis, but the extent to which it does 
remains unclear. Additionally, we are unsure whether the changes in DSS-induced colitis 
accurately reflect what is seen in human ulcerative colitis because DSS is just a model 
and therefore does not perfectly recapitulate UC. DSS acts as a colitogen, which may 
enable iron to alter disease activity in a way that would not occur in ulcerative colitis. 
Future studies in humans are needed to determine whether oral iron truly does exacerbate 
UC disease activity (see below).    
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Future Directions 
 Future studies will examine colonic iron absorption in other pertinent digestive 
diseases, such as celiac disease. Celiac disease is a gluten-sensitive autoimmune 
condition that leads to severe inflammation in the small intestine (8). Iron deficiency 
anemia (IDA) is often the presenting clinical feature because duodenal villi are severely 
damaged and iron absorption is impaired (5). We, therefore, expect increased expression 
of colonic iron transporters to help compensate for iron deficiency. This study could be 
accomplished by obtaining IRB approval to collect colonic biopsy specimens from 
patients with suspected or diagnosed celiac disease. RT-qPCR, Western blot analysis, 
iron uptake studies, and immunostaining could then be performed on the biopsy 
specimens to determine abundance and localization of DMT1 and FPN1.   
 It would also be interesting to study colonic iron transporters in patients who have 
had a roux-en-Y gastric bypass for weight loss purposes (16). These patients have the 
stomach shrunk down and attached to the jejunum, completely bypassing the duodenum 
where iron absorption typically occurs (1). We would expect colonic iron absorption to 
be increased in these patients, as well. This could be studied in animals via a location-
specific knockout or by performing bypass surgery.  
 In addition to characterizing colonic iron absorption in various other conditions, 
we also plan to finish our animal study that seeks to determine whether oral iron 
exacerbates DSS colitis. We specifically want to know whether iron causes pathogenic 
changes in the microbiome. Terminal restriction fragment length polymorphism (TRFLP) 
is being carried out using specially designed degenerate primers in order to be able to 
detect changes in as many species as possible. We are particularly interested in whether 
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iron impacts the amount of butyrate-producing bacteria (BPB) because butyrate, a short 
chain fatty acid (SCFA), promotes colonic health and has various anti-inflammatory 
effects (4).  
The animal study is a good first step in evaluating the safety of oral iron 
supplementation, but a human clinical trial is needed in order to definitively determine 
whether oral iron exacerbates UC disease activity. We have already obtained IRB 
approval for this study (Protocol # 1711842175- “The effect of oral iron administration 
on the microbiome of patients with ulcerative colitis”).  
HUMAN CLINICAL TRIAL 
The clinical trial is setup very similarly to the animal study with four groups: 
control, control + iron, UC, UC + iron. Control groups will be given a placebo twice a 
day for two weeks, while iron groups will be given 325 mg ferrous sulfate. Disease 
activity will be monitored using the Modified Mayo Scoring System. Fecal samples will 
be collected at the beginning and end of the two-week treatment window to determine 
changes in the microbiome via TRFLP analysis.  
Procedures  
1. Recruiting- Patients will be recruited during a previously scheduled office visit or 
will be identified via a chart review and contacted by phone to see if they are 
interested in participating in the study.  
2. Consent- Written informed consent will be obtained during a visit to see Dr. 
Kupec at the Digestive Diseases clinic at WVU. Patients recruited via chart 
review and phone call will be brought into the clinic free of charge to complete 
the enrollment process.  
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3. Collecting data- Patients will be given all the necessary supplies during the office 
visit to be able to complete the study. They will be given enough medication (iron 
or placebo) to last for the full 2 weeks of the study free of charge. Dr. Kupec will 
give them the necessary supplies to collect 2 fecal samples and will help them 
complete the pre-survey. The patients will provide the first fecal sample either in 
office or at their earliest convenience. Once they have provided the first sample 
they will begin taking their assigned medication twice a day for two weeks. On 
day 14 they will return to clinic to provide the second fecal sample and complete 
the post-survey with the help of Dr. Kupec.  
4. How findings will be shared- All samples will be de-identified using a numbering 
system. Identifiable information will not be used in the final manuscript. 
Standard of Care 
Participants enrolled in this study will be given a standard dose of oral iron 
supplementation (325 mg ferrous sulfate). This medication is available over the counter 
and is the first line treatment for iron deficiency anemia. Should the patient experience 
any adverse symptoms, such as gastrointesintal distress, they will be told to discontinue 
the medication, as is standard practice. 
Group Assignment 
Subjects with no known colonic pathology (control) or subjects with active UC 
will be randomly assigned to receive oral iron or a placebo using an online randomization 
program (graph pad). Dr. Kupec will be responsible for randomizing patients and will not 
inform them or the other researchers who is receiving what medication. 
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Drug/Substance/Biologic  
The placebo contains no active ingredients. Ferrous sulfate 325 mg is 
commercially available over the counter and is used to treat iron deficiency anemia, the 
most common extra intestinal manifestation of ulcerative colitis. 325 mg twice a day is a 
standard dose. Possible side effects include mild gastrointestinal symptoms such as 
nausea, bloating, and diarrhea. There are no known serious adverse effects associated 
with iron supplementation. If the patient is experiencing any distress or discomfort they 
can stop taking the medication at any time. Both medications (ferrous sulfate and 
placebo) will be kept in a locked cabinet in the Digestive Diseases clinic at WVU. The 
clinic is temperature controlled and we will comply with the recommended storage 
conditions of the medications. 
Risk Assessment 
This study is classified as more than minimal risk, and therefore, required full 
board review and monitoring for harm. The placebo drug does not have any active 
ingredients, so there are no risks or discomforts associated with its use. Ferrous sulfate is 
commercially available over the counter and is considered safe for use. The body has a 
mechanism that only allows absorption of iron that is needed, so any excess iron will be 
passed through the digestive system and excreted in the feces. Oral iron supplementation 
is associated with some adverse gastrointestinal symptoms, including nausea, 
constipation, upset stomach, flatulence, black or tarry stools, and diarrhea. The potential 
risks are expected to be minimal in occurrence and severity.  
Patients will be told about potential side effects of oral iron supplementation prior 
to being enrolled in the study. These include gastrointestinal symptoms such as bloating, 
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abdominal pain, and diarrhea. Some mild GI discomfort is expected, but if the symptoms 
persist or become excessive patients will be told to contact their gastroenterologist (Dr. 
Kupec) and may discontinue the medication. Discontinuing the medication will be 
sufficient to stop symptoms. Monitoring for harm will occur on a case-by-case basis and 
will depend on patients self reporting their symptoms. 
Subjects 
In order to participate in this study, patients must be at least 18 years of age. 
Exclusion criteria includes patients currently receiving iron supplementation, antibiotic 
use or blood transfusion in the past 3 months, infectious diseases (such as HIV and 
hepatitis), and history of intolerance to oral iron supplementation. The control group will 
consist of patients with no known colonic pathology. The active ulcerative colitis group 
will have active disease activity on biopsy or positive clinical symptoms, as determined 
by a gastroenterologist.  
Selection of patients for participation in this study will be equitable across race, 
gender, ethnicity, etc. All patients presenting to the digestive diseases clinic who fit with 
the inclusion criteria will be considered for participation in this study. No preference will 
be given for a specific sex, gender, ethnicity, etc. As long as the patient is 18 years or 
older they may be recruited into the study. 
Data Protection 
Samples will be deidentified using a numbering system. The first number will 
correlate to the patient enrolled and the second number will indicate the sample. For 
example, patient 3-1 will be patient #3, sample 1 (day 0). 3-2 will be patient #3, sample 2 
(day 14). The data will be kept for as long as Dr. Rajendran maintains an active lab at 
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WVU (5+ years). All physical data will be kept in non-patient care areas of WVU 
Hospital or the Health Sciences Center in a locked file cabinet behind a locked door. All 
electronic data will be stored on computers that are password protected. Electronic data is 
stored in software that requires a password to access and a password for login. Physical 
data will be destroyed using locked shredder bins. Electronic data that needs to be deleted 
will be done so using an IT protocol. 
Financial Considerations 
The subjects will be provided a $25 gift card upon completion of the study. 
Institutional Biosafety Approval (IBC) 
IBC approval has been obtained (protocol 17-11-03).   
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Abstract  
 
Historically used as an anesthetic, chloroform is a halogenated hydrocarbon that is 
associated with central nervous system depression, arrhythmias, and hepatotoxicity. It is 
no longer used clinically, but accidental and intentional poisonings still occur. We report 
a case of chronic chloroform abuse leading to severe hepatotoxicity in a 26-year-old male 
graduate student. The patient presented to the emergency department with a three-day 
history of abdominal pain, dehydration, and scleral icterus. He drank several beers the 
night before the onset of symptoms, but denied taking acetaminophen, ibuprofen, or other 
drugs. An extensive work-up revealed an aspartate aminotransferase (AST) of 13,527 
U/L and alanine aminotransferase (ALT) of 8,745 U/L, but the cause of his liver injury 
could not be determined. It was not until many months later that the patient admitted to 
inhaling chloroform in the weeks leading up to his illness. 
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Introduction  
 
Chloroform is no longer used to induce anesthesia, but it is commonly used as a solvent 
in laboratory settings and poisonings still occur. There are several cases that describe 
chloroform-induced hepatotoxicity following suicide attempts, but this is the first known 
report of chronic, recreational chloroform abuse (1, 2). The patient was a graduate student 
who inhaled chloroform obtained from his laboratory for several months leading up to his 
hospitalization. He did not disclose that initially because he did not feel comfortable 
discussing his drug use. Herein we describe the clinical presentation of chronic exposure 
to chloroform and highlight the importance of establishing a strong rapport with patients 
in order for there to be an open and honest dialogue about substance abuse. 
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Case Presentation 
	  
A 26-year-old male graduate student presented to the emergency department with 
a three-day history of nausea, vomiting, and abdominal pain. He additionally complained 
of dark urine with sediments, dehydration, and scleral icterus. Laboratory evaluation 
revealed an aspartate aminotransferase (AST) of 13,527 U/L, alanine aminotransferase 
(ALT) of 8,745 U/L, and ferritin of >40,000  ng/mL. His total bilirubin was 5.5  mg/dL 
and international normalized ratio (INR) was 1.95, suggesting a chronic liver injury 
(Table 1). The patient reported drinking four to five beers the night before the onset of 
symptoms but denied taking acetaminophen, ibuprofen, or other drugs. He was given 
intravenous saline and admitted to the hospital for further evaluation. 
Given his presentation and significant transaminase elevation, drug-induced 
hepatitis or viral hepatitis was suspected, while ischemic hepatopathy was unlikely. Right 
upper quadrant ultrasound was unremarkable. Acetaminophen, salicylate, and tricyclic 
levels were negative. Mononucleosis, human immunodeficiency virus, cytomegalovirus, 
antinuclear antibody, and viral hepatitis panel were also negative. Herpes simplex and 
varicella zoster IgG were positive, likely due to prior infection or immunization. 
He remained stable during hospitalization and his liver enzymes began to trend 
downward, so he was discharged two days after admission. At six-week gastroenterology 
follow-up visit, his liver enzymes had returned to normal and he reported complete 
resolution of symptoms. The remainder of the pending laboratory evaluation (smooth 
muscle antibodies and hemochromatosis testing) returned negative. 
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The etiology of this patient's hepatitis remained unknown until many months later 
he admitted to inhaling chloroform. He described recreational huffing, to the point of 
unconsciousness, twice weekly over several months. This information was not 
volunteered at the time of presentation because the patient was embarrassed and did not 
feel comfortable discussing substance abuse with his physicians. 
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Discussion 
Chloroform is a volatile organic compound that is commonly used as a solvent, 
cleanser for plastic compounds, and acrylic adhesive (3). Exposures can occur 
accidentally or intentionally in various occupational settings including cleanrooms, 
laboratories, and factories. Several cases describe hepatotoxicity from acute chloroform 
exposure, but we provide the first known report of severe hepatitis resulting from 
chronic, recreational chloroform abuse. The liver enzyme elevations seen in our patient 
were significantly higher than those following acute consumption (AST 1,160 U/L, ALT 
3,560 U/L) and suicide attempts (AST 1,513 U/L, ALT 2,717 U/L) [1, 2]. Regardless of 
the intent of use, liver injury is largely the result of phosgene, a toxic metabolite formed 
via cytochrome P450 2E1 (4). Phosgene participates in acylation reactions with proteins, 
carbohydrates, and lipids, which depletes glutathione stores and leads to severe oxidative 
damage and ultimately hepatocellular steatosis and necrosis (5). Concomitant alcohol 
consumption, as seen in our patient, magnifies this effect via cytochrome P450 enzyme 
induction (6). 
The patient experienced significant transaminase elevation, but physicians could 
not determine the cause because they were missing key information. People with access 
to chemicals, either professionally or educationally, should receive a thorough 
occupational history and any exposures should be classified and quantified. For example, 
chloroform poisoning should be considered in graduate students, cleaners, and factory 
workers with unexplained liver injury. If questions arise about treatment, physicians 
should then reference the material safety data sheets (MSDS). In addition, completion of 
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a social history to establish comorbid conditions or behaviors will allow accurate 
guidance for further testing or care. 
The nonspecific nature of the patient's symptoms and his undisclosed drug use 
made it hard to establish the correct diagnosis. People who use illicit substances are often 
reluctant to divulge such information because of the stigma associated with drug use. In 
order to overcome this, healthcare providers must establish a strong, professional rapport 
with patients so that there can be an open and honest dialogue. Additionally, a thorough 
occupational history can help uncover potential exposures. In conclusion, chloroform and 
other halogenated hydrocarbons can lead to severe hepatotoxicity and should be 
considered in certain populations who present with unexplained liver injury. 
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Consent  
 
Written informed consent was obtained from the patient. 
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Table 1 
Laboratory findings. 














AST 8-48 U/L 13,527 9,319 5,137 2,140 23 








mg/dL 3.5 2.6 4.7 5.4 0.3 




sec 21.7    22.2 16    
INR 0.8-1.2 1.95    1.99 1.45    
Ferritin 20-300 ng/mL       > 40,000    503 
Ammonia 15-50 umol/L 120       47    
Urine Protein 0 mg/dL 30             
Urobilinogen 0 mg/dL 4             
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 Coin ingestion is a common problem in pediatrics. Previously it was treated via 
endoscopic removal, however, newer techniques allow for advancement of the coin into 
the stomach to be passed naturally. We present a case of coin ingestion by a 14-month-
old boy that was treated by esophageal bougienage. A bougie (long, fixed rod) inserted 
into the child’s esophagus successfully propelled the coin into the stomach without need 
for a pediatric gastroenterologist nor the risks associated with anesthesia. The patient was 
discharged 30 minutes after the procedure and eventually passed the coin on his own 
without complications. Esophageal bougienage would be particularly useful in rural 
emergency departments that lack the resources of pediatric endoscopy and could have 
avoided the costly transfer of this patient to a larger facility.  
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Introduction 
 
 Foreign body ingestion is a significant public health concern that results in tens of 
thousands of emergency room visits and approximately 1,500 deaths annually (1). Coins 
are the most commonly ingested object by children, accounting for approximately 60% of 
cases (2). Historically, the gold standard treatment for coin ingestion was endoscopic 
removal, but other methods have proven to be more cost effective and are equally safe 
and efficacious (3–5). We present a case where a coin lodged in the esophagus was 
successfully treated with esophageal bougienage.  
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Case Presentation 
 
 A 14-month-old male child presented to an emergency department (ED) in rural 
West Virginia with the chief complaint of refusing perioral (PO) intake, drooling, and 
spitting up. His mother suspected that he might have ingested something, as he was 
known to frequently put objects in his mouth. On examination, the patient did not appear 
to be in acute distress and his vitals were stable. An anterior-posterior x-ray demonstrated 
a coin-shaped object in the cervical esophagus (Figure 1A). The child was transferred to a 
larger, more equipped hospital for care.  
Esophageal bougienage using a 30 French weighted Hurst bougie was performed 
by a physician in the ED. The patient remained vitally stable throughout the procedure 
with a respiration rate of 32, heart rate of 152, oxygen saturation of 96%, and breath 
sounds equal bilaterally. The coin was successfully advanced into the stomach, as 
evidenced by x-ray (Figure 1B). Following the procedure, the child tolerated PO intake 
and was discharged after 30 minutes of supervision. The patient eventually passed the 
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Discussion 
 
 Coin ingestion should be considered in young children presenting to the 
emergency department (ED) with dysphagia and odynophagia (6). Diagnosis is achieved 
via radiographic evaluation, which enables identification and localization of the foreign 
body (7). The thoracic inlet is the most common site of impaction due to esophageal 
narrowing, as was the case in our patient (8). A variety of techniques can be used to 
remove the object, but the most rapid and cost effective method is esophageal bougienage 
(9). This procedure involves sticking a bougie, a long fixed rod, into the esophagus to 
dislodge the coin. Once in the stomach, the coin then passes through the remainder of the 
digestive tract and is excreted in the feces.  
 There are many benefits to esophageal bougienage compared to other treatment 
options. The average length of hospitalization for a patient who undergoes endoscopic 
removal is 22.7 hours versus 2.15 hours spent by those who receive bougienage (10). It is 
also substantially less expensive, with an average price tag that is 1/10 the cost of 
endoscopy (3). Additionally, bougienage doesn’t require sedation, therefore lowering the 
risk of complications (11).  
Esophageal bougienage would be particularly useful in rural EDs that lack 
pediatric endoscopy, thus necessitating transport to another hospital (7). Our patient was 
transferred to a larger hospital that was more than 30 miles away, which delayed 
treatment and was costly for the family and the healthcare system. Esophageal 
bougienage is the preferred treatment in such settings because it can be performed 
anywhere without any specialists.  
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 In conclusion, we present a case of pediatric coin ingestion that was successfully 
treated with esophageal bougienage. Bougineange is a safe, rapid, and cost-effective 
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Figure 1: Anterior-posterior x-ray visualization of the ingested coin before and after 
treatment. A: The coin is visible near the thoracic inlet. B: Esophageal bougienage 























“Science is simply the word we use to describe  
a method of organizing our curiosity.” 
 
- Tim Minchin 
